Regulation of Transgenic Class II Major Histocompatibility Genes in Murine Langerhans Cells  by Longley, Jack et al.
Regulation of Transgenic Class II Major 
Histocompatibility Genes in Murine 
Langerhans Cells 
Jack Longley, * Tie-gang Ding, * Ditza Levin,t:j: Julia Lewis, * Richard Edelson, * Robert Tigelaar, *t and 
Richard Flavell t:j: 
*Department of Dennatology (Yale Skin Disease R esearch Center) and tSection of lmmunobiology, Yale University School of 
Medicine, and the :j:How ard Hughes Medical Institute, New Haven, Connecticut, U.S.A. 
I-E is a class II ntajor histocontpatibility complex 
molecule norntally expressed by Langerhans cells. A 
series of transgenic ntice were developed previously 
that carry E a d gene constructs with promoter-region 
deletions that cause expression ofI-E by different cell 
types when maintained on a B6 (I-E[ -]) genetic 
background. To study cis-acting gene sequences that 
regulate expression of class II proteins by Langerhans 
cells, we identified transgenic I-E expression by tissue 
immunoperoxidase staining and by epiderntal cell 
suspension intntunofluorescence cytometry. Mice 
with a trans gene containing 1.4 kilobase pairs (kb) of 
flanking sequence 5 ' to the E a initiation site ex-
pressed barely detectable levels of I-E on a tiny 
percentage of Langerhans cells, indicating that se-
quences prontoting Langerhans cell expression of E a 
exist between 2.0 and 1.4 kb 5 ' of the E a initiation 
site. Removal of an additional 170 bp of 5 ' flanking 
sequence caused near-normal levels o f expression by 
pecific immune responses are generated and regulated 
through the expression of genes encoded by the major 
histocompatibility complex (MHC), the products of 
which are cell- surface glycoproteins that combine with 
antigenic pep tides to form complexes recognized by T 
cells [1,2]. Class II M HC molecules, also known in the mouse as 
immune-response- associated (Ia) antigens, are heterodimers com-
posed of two chains of approximately equal sizes termed Q' and (3 
[3,4]. Two types of murine la antigens, called I-A and I-E, are 
normally coexpressed on thymic epithelial and interdigitating re-
ticular cells as well as on B lymphocytes, macrophages, and 
dendritic cells [5- 10]. Thymic expression of la molecules is critical 
both for the induction of tolerance to self antigens [10,11] and for 
selection of self-MHC- restricted T cells [12-14]. For antigen-
specific activation outside of the thymus, CD4( +) T cells must 
interact with la molecules complexed with the specific antigen and 
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approximately one third of epiderntal Langerhans 
cells, which contrasts with studies that showed min-
intal transgene expression by splenic dendritic cells 
in these anintals. Thus, sequences between 1.4 and 
1.23 kb 5 ' of the E a initiation site decrease expression 
of I-E by epiderntal Langerhans cells, but enable I-E 
expression by splenic dendritic cells. These studies 
identify Langerhans cell-specific regulatory se-
quences and genetic regions controlling major histo-
compatibility complex class II gene expression in 
Langerhans cells and splenic dendritic cells. The 
genetic regions identified may be particularly intpor-
t ant because differential regulation of class II major 
hist ocompatibility complex protein synthesis b y 
Langerhans cells and dendriti c cells may be crucial t o 
intmune functions of intact anintals. K ey words: den-
dritic cells/antigen p resentation. ] I nvest D ermatoI104:329-
334, 1995 
expressed on the surface of antigen-presenting cells (APCs). Sur-
face expression of these la molecules is regulated and represents a 
pivotal point in control of the diverse immune processes requiring 
CD4( +) T cells, including cell-mediated immunity and the gener-
ation of antibodies by B cells. 
Dendritic cells are la( +) APCs that are especially active in the 
induction of primary antigen- specific immune responses [6]. The 
term dendritic cell may be applied to several populations of cells, 
the phenotypes and functional characteristics of which are dynamic, 
depending on their anatomic location and their history of exposure 
to various stimuli [15,16]. Langerhans cells are a type of dendritic 
cell found in the epidermis, where they are normally the only cell 
type that express la antigen [6,17]. When freshly isolated from 
epidermis, Langerhans cells can process antigen, and this function is 
associated with synthesis of la antigen [18-20]. More "mature" 
dendritic cells, isolated from spleen, retain the ability to present 
antigen but do not synthesize la antigen and are poor APCs [19,20]. 
Therefore, Ia antigen expression is differentially regulated in Lange-
rhans cells and splenic dendritic cells. This differential regulation 
may be crucial to directing the immune responses of intact organ-
isms to particular antigens [6,19,20]. 
The genetic basis for class II gene expression has been studied in 
vitro by transfecting specific gene constructs into various cell types, 
and in vivo by developing transgenic animals [10,21-28]. Strains of 
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mice exist in which the endogenous genes encoding the Ea chain of 
the I-E heterodimer are not expressed because of a mutation in the 
regulatory portion of the Ea gene [4]. Ea transgenes containing at 
least 2.0 kilobase pairs (kb) of 5' flanking DNA cause appropriate 
expression ofEa mRNA and surface protein in these mice [10,28-
30]. Transgenes containing less 5' flanking sequence (Ead genes) 
generally result in normal expression of I-E in the thymus of these 
animals but may result in lower levels of expression by specific 
peripheral cell types, partial expression by a given cell type, or 
expression limited to one or several of the cell types that express I-E 
in normal animals. Expression of I-E by B cells, macrophages, and 
splenic dendritic cells has been characterized in these animals, and 
specific 5' flanlcing sequences with cis-regulatory function in these 
cell types have been identified. However, no such studies have 
been made ofI-E expression by Langerhans cells [10,26,27,31]. 
In our current study, we examined expression ofI-Ea transgenes 
by Langerhans cells in these animals. We show that I-Ea expressed 
by Langerhans cells is regulated differently from that expressed by 
macrophages, B cells, and splenic dendritic cells, and we define 
specific regions in the 5' flanlcing sequences of the Ea gene that 
differentially control that expression. Because dendritic cells are the 
main, if not the only, cells capable of priming CD4( +) T cells and 
initiating certain immune responses [6,7,32], characterization ofI-E 
expression by all dendritic cells in these transgenic animals is critical 
for precise understanding of the mechanisms of immune function 
restricted by I-E. Furthermore, identification of these specific 
regulatory sequences may allow precise targeting of Langer hans cell 
and dendritic cell gene expression. 
MATERIALS AND METHODS 
Generation of Transgenic Mice Generation of the experimental ani-
mals, including the embryo microinjection, E,/ gene subcloning, and 
analysis of DNA, have been described previously [10,26-30]. Two strains of 
transgenic mice with wild-type phenotype were used; strains 107 and EO'16 
[10,26,27]. 
Preparation of Cell Suspensions Mter sacrifice, the mice were soaked 
in 70% ethanol and shaved. Strips of body-wall skin were cut, the dermis 
was separated from fat, and the strips were placed dermal-side down in 0.3% 
trypsin in GNK (0.3% trypsin [type XI; Sigma, St. Louis, MO], 0.1 7% 
glucose, 1S0 mM NaCl, S mM KCI). Strips were incubated overnight at 
4°C, and the epidermis was removed the next morning by gentle scraping. 
The epidermis was placed in fresh trypsin, GNK, and 0.1% DNAse 
(deoxyribonuclease I; ICN, Irvine, CA) and incubated in a 37°C water bath 
with continuous shaking for 10 min. Medium A (Minimal Essential Medium 
[Gibco, Grand Island, NY] containing 10% fetal bovine serum, 1% Peni-
cillin/streptomycin, and 0.1 % DNAse) was added and the tubes were placed 
on ice. The cell preparation was filtered through nylon mesh to remove 
stratum corneum and hair, and the cells were washed in medium A and 
pelleted at 1000 rpm for 10 min at 4°C. Cells were further enriched in Ficoll 
(density 1.083) at 1200 rpm for 20 min at 4°C. Interface cells were harvested 
and washed twice in medium A. 
Epidermal Cell Culture For some experiments interface cells were 
cultured for 3 d at 37°C in RPMI 1640 medium supplemented with S% 
murine serum and 1 X antibiotic-antimycotic (Gibco). 
Epidermal-Sheet Preparation Ears were treated with Neet depilatory 
for 10 or 12 min, and the hair was wiped offwith a Kimwipe. The ears were 
rinsed in distilled water. The dermis and subcutaneous tissue were separated 
by blunt dissection from the underlying ear cartilage, and any remaining 
cartilage and fat were removed by scraping with the edge of a forceps. Ear 
skin was soaked in O.S M NH4 SCN at 37°C for 20 min (no CO2), and the 
epidermis was removed and washed three times in phosphate-buffered 
saline. The epidermal sheets were fixed in acetone (- 20°F) for 20 min and 
then washed and stored in phosphate-buffered saline at 4°C. 
Detection of Ia Activity I-A and I-E were detected with monoclonal 
antibodies 212.A (anti-I-A, IgG2a) [33] and 14.4.4s (anti-I_Ek •d , IgG2a) 
[34], respectively. An isotype-matched monoclonal antibody of irrelevant 
specificity was used as a control in all experiments. Other controls routinely 
performed to validate our results included staining of non transgenic litter-
mates (negative control) and of a naturally I-A and I-E( +) strain (SR, 
positive control). Note that the SR stain is homozygous for I-E and the 
experimental animals are heterozygous for the transgene. 
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Flow Cytometry To minimize binding of mouse monoclonal antibodies 
to surface Fe receptor, epidermal cells were incubated with S% mouse 
serum, and staining was performed in the presence of the same. After 
incubation with the primary monoclonal antibody (biotinylated 212.A or 
control antibody), the cells were washed three times and incubated with 
avidin-phycoerythrin (Becton-Dickinson, Bedford, MA), washed three 
times, and analyzed by flow cytofluorometry on a FACStar or FACScan 
(Becton-Dickinson) or EPICS XL-MCL (Coulter Corporation, Hialeah, 
FL) . For double staining, fluorescein isothiocyanate (FITC)-conjugated 
14.4.4s antibody was included in the primary incubation solution. To 
control for the presence of FITC, we used Fab-FITC of irrelevant specific-
ity. All flow cytometry results are presented as dot plots showing fluores-
cence intensity (logarithmic scales) on the ordinate and abscissa. At least 
10,000 events were accumulated for all plots shown. 
Immunohistochemistry Epidermal sheets were washed in 100 mM Tris 
(PH 7.2) and then stained with the Avidin-Biotin-Peroxidase complex 
technique (ABC, Vector Laboratories, Burlingame, CA) according to 
standard protocols. Immunohistochemical staining of thymus, lymph nodes, 
and spleen from selected animals confirmed the patterns of I-E expression 
reported previously in these animals (our unpublished data). 
RESULTS 
As expected, animals with trans genes that had previously been 
reported to express I-E with a normal tissue distribution and at 
normal levels (wild-type phenotype) showed a 1:1 correspondence 
between expression of endogenous I-A and expression of I-E on 
Langerhans cells when analyzed by flow cytometry using two-color 
immunofluorescence staining or in situ by immunoperoxidase (Fig 
lA,B). However, animals with a transgene containing only 1.4 kb 
of 5' flanlcing sequence and which show restricted expression ofI-E 
[10] showed minimal expression of I-E by epidermal Langerhans 
cells. Faint expression was identified in only one of five epidermal-
sheet preparations, and there was minimal or no change in the 
fluorescence-activated cell sorter profile of these animals' Langer-
hans cells when stained for I-A and I-E as compared to staining for 
I-A alone (Fig lC, strain 46.2). This contrasts with studies that 
showed expression of I-E by 100% of dendritic cells isolated from 
spleens of these animals (Table I) [31]. Short-term culture caused 
these Langerhans cells to express near-normal levels of I-E, like 
splenic dendritic cells from the same animals (Fig 2B). Strilcingly, 
removal of an additional 170 bp of the 5' flanking sequence resulted 
in a rightward shift (increase in mean channel fluorescence) in the 
cytofluorometric profile of almost the entire population of Lange-
rhans cells, indicating expression of transgenic I-E by most epider-
mal Langerhans cells (with normal levels of I-E expressed by 
approximately one third) (Fig lD, strain 244.8). This increased I-E 
expression was confirmed by the easy detection of a population of 
I-E( +) epidermal dendritic cells in situ. These results indicate that 
the 170-base pair fragment between -1.4 and -1.23 kb 5' to the 
initiation codon of the Eo< gene contains sequences suppressing 
expression of I-Eo< by epidermal Langerhans cells. The effects of 
culturing Langerhans cells from the 244.8 strain were not as clear 
cut as those seen with the 46.2 stain; after 3 d there was continued 
I-E expression by most 244.8 Langerhans cells, although some 
experiments showed a slightly decreased intensity of expression, 
particularly in the group of Langerhans cells with low baseline 
levels of expression (Fig 2C, lift upper sector). For example, the 
mean channel (x axis) fluorescence was 69.16 for freshly isolated 
Langerhans cells, versus 31.68 for cultured Langerhans cells in one 
set of experiments. Similar results were seen in two of three 
experiments. One experiment showed no detectable change. As 
shown in Table I, studies of splenic dendritic cells from these 
animals showed faint expression, less than 5% of control, in this 
strain [31]. This discrepancy in expression of I-E by epidermal 
Langerhans cells and splenic dendritic cells points to specific 
sequences regulating phenotypic heterogeneity of dendritic cell 
populations within different anatomic locations. 
Removal of an additional 880 bp of 5' flanking sequence resulted 
in variable expression in two different strains, which parallel the 
expression in B cells seen previously in these transgenic lines (Fig 
lE,F). Near-normal levels of expression were seen in the majority 
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Figure 1. Different genetic regions promote or suppress expression of transgenic MHC class II molecules by murine epidermal Langerhans 
cells (LC). Figure shows cytometric and ill situ detection of the MHC class II antigens I-A and I-E in transgenic mice. For flow cytometry, epidermal cells 
were stained with biotinylated anti-I-A and FITC-anti-I-E (or FITC-Iabeled antibody of irrelevant specificity as a control), followed by phycoerythrin 
(PE)-avidin. Data fields are drawn to indicate the population of phycoerythrin (+ )/FITC( -) Langerhans cells (I-A[ + ]/I-E[ -], upper left) and phycoerythrin 
(+ )/FITC( +) Langerhans cells (I-A[ + ]/I-E[ + ], upper right). III situ studies used biotinylated primary antibodies with an avidin/peroxidase detection system. 
Photomicrographs were 400 X original magnification. A and B, positive controls. A) Results using 5R, a nontransgenic strain that normally expresses I-E; 
B) results using animals with wild-type expression of their transgene. Animals with transgenes containing progressively shorter fragments of 5 ' regulatory 
sequence (strains 46.2, 244.8, 275.6, and 273.4) are displayed (C,D,E,F). Animals with I-E expression limited to the thymus (36.2) are shown (G) for 
comparison and serve as perfect specificity controls for the reagents. Note that I-E expression by Langerhans cells in strain 46.2 (C) was minimal, and was 
found in s itu in a patchy distribution in only one of five animals studied . 
Table I. Expression of Membrane I-E on Dendritic Cells (DC) and Langerhans Cells (LCY 
Transgenic Line 
Ea16, 107-1 
(Wild Type) 46.2 244.8 275.6 273.4 36.2 
5' regulatory sequences (kb) 2.0 1.4 1.23 0.35 0.35 1.4 + vector 
Percent I-E( + ) 
LC 100 < 5 > 95 > 95 > 95 0 
DC 100 100 < 5 100 35 0 
n The staining and fluorescence-activated cell sorter analysis of Langerhans cell s were performed as described in Materials and Methods. The data for characterization of I-E 
expression on dendritic cells are summarized from Levin et al r31). 
of Langerhans cells in strain 275.6 (Fig lE). This line was shown 
previously to have an essentially wild-type pattern ofI-E expression 
in the thymus and by peripheral B cells and splenic dendritic cells, 
but impaired expression by macrophages [31 ,3 5] . A second strain 
containing the same Ea d construct showed a similar although lower 
pattern of expression by Langerhans cells (strain 273.4, Fig IF). 
This strain also showed a reduction of I-E expression on B cells , 
macrophages, and splenic dendritic cells, but normal expression in 
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Figure 2. Expression of transgenic MHC class n molecules is 
altered by Langerhans cell culture. Flow cytometry of Langer hans cells 
cultured for 3 d and stained for I-A (FITC label, y axis) and I-E 
(phycoerythrin [PEl label, x axis). A) Wild-type cultured Langerhans cells 
show I-A( +), I-E( +) phenotype similar to that seen in freshly isolated 
Langerhans cells from the same strain (compare with Fig tB). B) Animals 
with trans genes containing 1.4 kb of 5' regulatory sequence (strain 46.2) 
show a marked increase in I-E expression, with a phenotype similar to that 
of dendritic cells from these animals (compare with Fig te, and see Table 
I) and freshly isolated or cultured wild-type Langerhans cells. C) Langer-
hans cells from animals with transgenes containing 1.23 kb of 5' regulatory 
sequence (strain 244.8) show minimal changes after culture. 
the thymus [31,35]. This variation between strains containing the 
same transgene construct is consistent with position effects from 
different trans gene insertion sites and was discussed previously for 
these two strains [35]. The addition of vector DNA to the trans gene 
suppresses expression by peripheral B cells, macrophages, and 
dendritic cells, as well as by epidermal Langerhans cells (Fig 1 G, 
strain 36.2). 
DISCUSSION 
The series of mice that we have described, in which transgenic I-E 
is expressed by different cells, provides a valuable resource for 
investigating the role of I-E in immune responses and for identify-
ing regulatory sequences that are specific or different cell types. 
However, the utility of these animals for in vivo studies depends on 
complete and accurate identification of all potentially I-E( +) cells. 
Previous studies of these animals focused on expression of I-E by 
thymic cells, splenic dendritic cells, peripheral macrophages, and B 
cells [11,26-31]. Expression of transgenic I-E by Langerhans cells 
has not been characterized previously, so any attempts to analyze 
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I-E-related immune functions usmg these animals are compro-
mised. 
In this report, we characterized the expression of I-E by Langer-
hans cells in these animals. These studies used multiple founder 
lines in all cases, and consistent expression of transgenes was 
obtained except in the lines 275.6 and 273.4. These lines (and one 
other which shows exactly the same expression pattern as 273.4) 
[26] were obtained from a construct with approximately 0.3 kb of 
5' flanking DNA. Perhaps this short segment renders this transgene 
more susceptible to position effects. The lines used in this study, 
with the exception of275.6, are characteristic of the trans gene used 
and do not represent an aberrant expression pattern derived from a 
single founder line with a single integration site. 
Of note is the transgenic strain 36.2, in which the trans gene 
contains a portion of vector in addition to 1.4 kb of 5' flanking 
sequence. These animals are important because they have normal 
expression of I-E in the thymic cortex and significant, though 
reduced, expression in the medulla; this expression permits both 
positive and at least partial negative selection of T cells capable of 
recognizing antigen in the context of I-E. As a consequence, these 
mice are tolerant to I-E in functional immunoassays [10]. Our 
current study, combined with previous work, demonstrates that 
these animals lack I-E expression on all known APCs present in the 
periphery and thus identifies these animals as ideal recipients in 
adoptive transfer experiments. The use of strain 36.2 as recipients of 
I-E( +) APCs from otherwise syngeneic animals allows precise, in 
vivo determination of the role of individual cell types in specific 
immune responses [31]. 
Additional features of our study are further delineation of specific 
5' regulatory sequences affecting class II molecule expression and 
identification of sequences that are critical for expression of I-E by 
Langerhans cells and dendritic cells. In particular, our studies of the 
46.2 strain show that cis-acting positive regulatory elements re-
quired for expression of I-E by most epidermal Langerhans cells in 
vivo exist between -2 and -1.4 kb 5' to the I-Ea initiation codon . 
Comparison of strains 46.2 and 244.8 indicates in situ that synthesis 
of I-E by Langerhans cells can be suppressed almost completely by 
sequences in the region between -1.4 and -1.23 kb of the I-E 
gene. However, when the 46.2 Langerhans cells are cultured for 3 
d, they express I-E like the dendritic cells from these same animals. 
This observation is not surprising, given the well-documented 
tendency for Langerhans cells to resemble dendritic cells after 
exposure to granulocyte macrophage-colony-stimulating factor 
produced by keratinocytes during isolation and culture [36,37]. 
This finding suggests that microenvironmental factors may be the 
major difference between Langerhans cells and other dendritic cells. 
It also suggests that the occasional finding of slight in situ expression 
of I-E on a tiny fraction of epidermal Langerhans cells in the 46.2 
strain could be a result of changes induced by the preparation of 
epidermal sheets. Unlike the results with strain 46.2, our experi-
ments were not able to detect significant changes (decreases) in I-E 
expression by cultured 244.8 Langerhans cells. Interpretation of this 
finding is problematic because I-E expression normally increases 
during culture [38] and because the 3-d culture may not be long 
enough for loss of previously synthesized I-E molecules. 
The 170-base pair region highlighted by these studies contains 
sequences, known as the X'Y' -box [39], that promote I-E expres-
sion in other cell types and that are therefore candidates for 
regulating expression of I-E in Langerhans cells. In contrast to the 
situation in epidermal Langerhans cells, 100% of splenic dendritic 
cells and peritoneal macrophages express I-E when these sequences 
are at the 5' end of their transgenes [31]. Sequences between -1.23 
and 0.35 of the gene decrease I-E expression by all splenic dendritic 
cells and can completely supprt:!ss expression ofI-E by most of these 
cells, but have no effect on a large subset of epidermal Langerhans 
cells. This segment contains a sequence known as the W -box [40], 
which is required for expression of I-E in some cell types. There-
fore, this area and the area immediately 5' to it are implicated in the 
reciprocal regulation ofI-E synthesis by epidermal Langerhans cells 
and splenic dendritic cells. The X'Y'- and W-box sequences, or 
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intervention directed at them, might be useful in differentially 
manipulating expression of genes by Langerhans cells and splenic 
dendritic cells, and are prime targets for further research. More 
detailed analysis may be possible as techniques for culturing 
Langerhans cells and dendritic cells become more sophisticated 
[41-44] and as well-characterized Langerhans and dendritic cell 
lines become more widely available [45,46]. 
Langerhans cells are bone-marrow- derived dendritic epidermal 
cells that are potent presenters of both alloantigen and exogenously 
acquired antigen in the context of class II MHC molecules 
[17,36,47,48]. Langerhans cells undergo phenotypic and functional 
changes in vitro when isolated from the epidermis, and in vivo when 
they migrate to regional lymph nodes after antigen sensitization 
[18-20,36,38]. In particular, after antigen exposure in vivo, they 
acquire the ability to sensitize T cells and stimulate T -cell-
dependent, B-Iymphocyte antibody responses [18,19]. The ability 
to process antigen by Langerhans cells correlates with their level of 
biosynthesis of class II molecules and expression of invariant chain 
[20]. Cessation of antigen processing and class II molecule synthesis 
may be crucial for transportation of antigen from the skin, where it 
is encountered, to the lymphoid organs, where a specific response 
is generated. This same mechanism may help control presentation 
of endogenous antigens. Therefore, synthesis of MHC molecules 
by these cells appears to be a major point of regulation for primary 
immune responses, and understanding the molecular basis of its 
control may allow more precise manipulation of the immune 
system [20]. Our studies implicate the regions of the I-E gene 
between -1.4 and -1.23 kb, and between -1.23 and -0.35 kb, 
which contain the elements known as the X'Y' -box and the 
W-box, respectively, as being crucial in the differential regulation 
of class II MHC expression by Langerhans cells and dendritic cells. 
This region and these elements may play major roles in the control 
of immune responses. 
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ANNOUNCEMENT 
An international symposium titled "Biological Events in Cutaneous Inflammation" will be held 
in Kiel, Germany, October 19-21, 1995. The topics will be the role of keratinocyte in 
cutaneous inflammation, leukocyte adhesion in early inflammation, mechanisms of cellular 
infiltration, Langerhans cell biology, cell-specific recruitment, proteolysis, fibrosis in cutaneous 
inflammation, and genodermatoses: recent advances. 
The meeting will consist of invited oral presentations. Abstracts will be accepted for oral or 
poster presentation. Deadline for abstract submission is August 1, 1995. For further informa-
tion contact Ulrich Mrowietz, M.D., Department of Dermatology, University of Kiel, 
Schittenhelmstrasse 7, 24105 Kiel, Germany. FAX: (49) 431-5971543. 
